Schwameis Richard, Grimm Christoph, Petru Edgar, Natter Camilla, Staudigl Christine, Lamm Wolfgang, Koelbl Heinz, Krainer Michael, Brodowicz Thomas, Reinthaller Alexander, Polterauer Stephan
Department of General Gynaecology and Gynaecological Oncology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Obstetrics and Gynaecology of the Medical University of Graz, Graz, Austria.
PLoS One. 2015 Aug 6;10(8):e0133838. doi: 10.1371/journal.pone.0133838. eCollection 2015.
C-reactive protein (CRP) has previously been shown to serve as a prognostic parameter in women with gynecologic malignancies. Due to the lack of valid prognostic markers for uterine leiomyosarcoma (ULMS) this study set out to investigate the value of pre-treatment CRP serum levels as prognostic parameter.
Data of women with ULMS were extracted from databases of three Austrian centres for gynaecologic oncology. Pre-treatment CRP serum levels were measured and correlated with clinico-pathological parameters. Univariate and multivariable survival analyses were performed.
In total, 53 patients with ULMS were included into the analysis. Mean (SD) CRP serum level was 3.46 mg/dL (3.96). Solely, an association between pre-treatment CRP serum levels and tumor size (p = 0.04) but no other clinic-pathologic parameter such as tumor stage (p = 0.16), or histological grade (p = 0.07), was observed. Univariate and multivariable survival analyses revealed that CRP serum levels (HR 2.7 [1.1-7.2], p = 0.037) and tumor stage (HR 6.1 [1.9-19.5], p = 0.002) were the only independent prognostic factors for overall survival (OS) in patients with ULMS. Patients with high pre-treatment CRP serum levels showed impaired OS compared to women with low levels (5-year-OS rates: 22.6% and 52.3%, p = 0.007).
High pre-treatment CRP serum levels were independently associated with impaired prognosis in women with ULMS and might serve as a prognostic parameter in these patients.
先前已证明C反应蛋白（CRP）可作为妇科恶性肿瘤女性患者的预后参数。由于子宫平滑肌肉瘤（ULMS）缺乏有效的预后标志物，本研究旨在探讨治疗前CRP血清水平作为预后参数的价值。
从奥地利三个妇科肿瘤中心的数据库中提取ULMS女性患者的数据。测量治疗前CRP血清水平，并将其与临床病理参数进行关联分析。进行单因素和多因素生存分析。
总共53例ULMS患者纳入分析。CRP血清平均（标准差）水平为3.46mg/dL（3.96）。仅观察到治疗前CRP血清水平与肿瘤大小之间存在关联（p = 0.04），但未观察到与其他临床病理参数如肿瘤分期（p = 0.16）或组织学分级（p = 0.07）之间存在关联。单因素和多因素生存分析显示，CRP血清水平（风险比2.7 [1.1 - 7.2]，p = 0.037）和肿瘤分期（风险比6.1 [1.9 - 19.5]，p = 0.002）是ULMS患者总生存期（OS）仅有的独立预后因素。与低治疗前CRP血清水平的女性相比，高治疗前CRP血清水平的患者OS受损（5年OS率：22.6%和52.3%，p = 0.007）。
治疗前高CRP血清水平与ULMS女性患者预后受损独立相关，可能作为这些患者的预后参数。
